Journal of Neuro-Oncology

, Volume 85, Issue 3, pp 319–328

Role of exclusive chemotherapy as first line treatment in oligodendroglioma

  • Marie Pierre Sunyach
  • Anne Jouvet
  • David Perol
  • Emmanuel Jouanneau
  • Jacques Guyotat
  • Laurence Gignoux
  • Christian Carrie
  • Didier Frappaz
Clinical Patient -Studies

DOI: 10.1007/s11060-007-9422-3

Cite this article as:
Sunyach, M.P., Jouvet, A., Perol, D. et al. J Neurooncol (2007) 85: 319. doi:10.1007/s11060-007-9422-3

Abstract

Purpose

The optimal therapy of oligodendrogliomas remains uncertain. Although chemosensitive, these tumors are not chemocurable. We investigated whether chemotherapy delays the need for radiation therapy (RT) without decreasing length and quality of survival.

Methods and materials

Among 89 patients treated for oligodendrogliomas at the Centre Léon Bérard of Lyon from 1982 to 1999, 59 patients fitted inclusion criteria, having had centrally reviewed pure oligodendroglioma requiring treatment. According to the WHO’s classification 35 patients had Grade III and 24, Grade II oligodendrogliomas.

Results

According to the intent to treat, patients were retrospectively classified in three groups as exclusive RT (Group 1), radio-chemotherapy (Group 2), or exclusive chemotherapy (Group 3). Median progression-free survival (PFS): was 47 months [95% confidence interval (CI) 39–56], and median overall survival (OS) was 109 months (95% CI 83–134). In univariate analysis, PFS was correlated with frontal location and WHO classification; OS was correlated with frontal location and Post-operative Karnosky performans status both appearing as independent prognostic factors for OS in multivariate analysis. There was no significant difference between the treatment groups with regard to PFS (P = 0.82) and OS (P = 0.64). In the group of patients treated with exclusive chemotherapy the 5-year PFS and OS rates were 44 and 71%, respectively.

Conclusion

Front-line exclusive chemotherapy results in prolonged OS in patients with confirmed pure oligodendroglioma. Whether this strategy improves quality of life remains debatable.

Keywords

Oligodendrogiloma Chemotherapy Radiotherapy 

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Marie Pierre Sunyach
    • 1
    • 6
  • Anne Jouvet
    • 2
  • David Perol
    • 3
  • Emmanuel Jouanneau
    • 4
  • Jacques Guyotat
    • 4
  • Laurence Gignoux
    • 5
  • Christian Carrie
    • 1
  • Didier Frappaz
    • 1
  1. 1.Radiotherapy and Neuro-Oncology UnitCentre Léon BérardLyonFrance
  2. 2.Neuropathology UnitHôpital WertheimerLyonFrance
  3. 3.Biostatistics Unit (UBET)Centre Léon BérardLyonFrance
  4. 4.Neurosurgery B UnitHôpital WertheimerLyonFrance
  5. 5.Neuro-Oncology Rhône-Alpes Network (ONCORA)Centre Léon BérardLyonFrance
  6. 6.Radiation Oncology DepartmentCentre Léon BérardLyonFrance